Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies. The SESAME-study

Autor: Y.J.L. Bodar, B.P.F. Koene, D. Meijer, P.J. Van Leeuwen, J.A. Nieuwenhuijzen, R.J.A. Van Moorselaar, N.H. Hendrikse, D.E. Oprea-Lager, A.N. Vis

Publikováno v: European Urology Open Science, Vol 21, Iss , Pp S66- (2020)

Externí odkaz: https://doaj.org/article/4da9e082b8104279895123ced9bb37b7

Standardized uptake values are adequate measures of [18F]DCFPyL PSMA PET/CT uptake in patients with low prostate cancer disease burden

Autor: Y.J.L. Bodar, B.P.F. Koene, B.H.E. Jansen, M.C.F. Cysouw, D. Meijer, N.H. Hendrikse, A.N. Vis, R. Boellaard, D.E. Oprea-Lager

Publikováno v: European Urology Open Science, Vol 21, Iss , Pp S69-S70 (2020)

Externí odkaz: https://doaj.org/article/b453661b83144b099cccf66b71451c9b

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and 18F-PSMA-PET/CT

Autor: Y.J.L. Bodar, W.I. Luining, B. Keizer, D. Meijer, A. Vellekoop, M. Schaaf, N.H. Hendrikse, R.J.A. Van Moorselaar, D.E. Oprea-Lager, A.N. Vis

Publikováno v: Bodar, Y J L, Luining, W I, Keizer, B, Meijer, D, Vellekoop, A, Schaaf, M, Hendrikse, N H, van Moorselaar, R J A, Oprea-Lager, D E & Vis, A N 2023, ' A prospective, multicenter head-to-head comparative study in patients with primary high-risk prostate cancer investigating the bone lesion detection of conventional imaging and 18F-PSMA-PET/CT ', Urologic Oncology: Seminars and Original Investigations, vol. 41, no. 4, pp. 205.e17-205.e24 . https://doi.org/10.1016/j.urolonc.2022.12.006
Urologic Oncology: Seminars and Original Investigations, 41(4), 205.e17-205.e24. Elsevier Inc.

Purpose: Prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) is an emerging staging tool for patients with primary high-risk prostate cancer (PCa). Patients with primary metastatic disease are staged us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d38108a5cd9d7b0c2cccb14d392ca1ae
https://doi.org/10.1016/j.urolonc.2022.12.006

Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial

Autor: Otto S. Hoekstra, G.J.C. Zwezerijnen, J.P. Van Der Voorn, Jakko A. Nieuwenhuijzen, N.H. Hendrikse, Daniela E. Oprea-Lager, B.H.E. Jansen, André N. Vis, D. Meijer, Y.J.L. Bodar, R.J.A. van Moorselaar, Ronald Boellaard

Publikováno v: Bodar, Y J L, Jansen, B H E, van der Voorn, J P, Zwezerijnen, G J C, Meijer, D, Nieuwenhuijzen, J A, Boellaard, R, Hendrikse, N H, Hoekstra, O S, van Moorselaar, R J A, Oprea-Lager, D E & Vis, A N 2021, ' Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens : is PSMA-targeted biopsy feasible? The DeTeCT trial ', World Journal of Urology, vol. 39, no. 7, pp. 2439–2446 . https://doi.org/10.1007/s00345-020-03490-8
World Journal of Urology, 39(7), 2439-2446. Springer Verlag
World Journal of Urology, 39(7). Springer Verlag
World Journal of Urology

Purpose In primary prostate cancer (PCa) patients, accurate staging and histologic grading are crucial to guide treatment decisions. 18F-DCFPyL (PSMA)-PET/CT has been successfully introduced for (re)staging PCa, showing high accuracy to localise PCa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9652f688ff045032509c9800dc0bee4
https://doi.org/10.1007/s00345-020-03490-8